Synapse

← Meletios Α. Dimopoulos

Papers by Meletios Α. Dimopoulos

Page 7 · newest first

  1. Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccineBritish Journal of Haematology · 2021
  2. Isatuximab for Relapsed/Refractory Multiple Myeloma: Review of Key Subgroup Analyses from the Phase III ICARIA-MM StudyFuture Oncology · 2021
  3. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent PlasmaViruses · 2021
  4. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristicsEuropean Journal Of Haematology · 2021
  5. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b studyBMC Cancer · 2021
  6. Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective StudyCancers · 2021
  7. TP53 mutations determined by targeted NGS in breast cancer: a case-control studyOncotarget · 2021
  8. Immune checkpoint inhibitor administration during pregnancy: a case seriesESMO Open · 2021
  9. Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition diseaseAmyloid · 2021
  10. Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study GroupJournal of Clinical Medicine · 2021
  11. Single-cell chromatin and transcriptome dynamics of Synovial Fibroblasts transitioning from homeostasis to pathology in modelled TNF-driven arthritis2021
  12. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patientsBMC Medicine · 2021
  13. Association of COVID ‐19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infectionEuropean Journal of Heart Failure · 2021
  14. MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor TreatmentCancers · 2021
  15. Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 PatientsCancers · 2021
  16. Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM TrialClinical Cancer Research · 2021
  17. Novel Nested-Seq Approach for SARS-CoV-2 Real-Time Epidemiology and In-Depth Mutational Profiling in WastewaterInternational Journal of Molecular Sciences · 2021
  18. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatmentBlood Cancer Journal · 2021
  19. A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple MyelomaCancers · 2021
  20. Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health WorkersCells · 2021
  21. Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipientsCell Reports · 2021
  22. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIABlood · 2021
  23. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONEBlood · 2021
  24. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. HydeHaematologica · 2021
  25. Chasing Hippos: Implications of YAP1 and TAZ Expression in Pregnancy-Associated Breast Cancer Tumorigenesis2021
  26. Neutrophil-to-Lymphocyte Ratio and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant Chemotherapy2021
  27. High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic EventsVaccines · 2021
  28. Daratumumab-Based Treatment for Immunoglobulin Light-Chain AmyloidosisNew England Journal of Medicine · 2021
  29. Managing complications secondary to Waldenström’s macroglobulinemiaExpert Review of Hematology · 2021
  30. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONEClinical Lymphoma Myeloma & Leukemia · 2021
  31. Ibrutinib plus rituximab for the treatment of adult patients with Waldenström’s macroglobulinemia: a safety evaluationExpert Opinion on Drug Safety · 2021
  32. Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques2021
  33. CDK4/6 Inhibitors and Arthralgia: A Single Institution ExperienceMedical Sciences · 2021
  34. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic riskAmerican Journal of Hematology · 2021
  35. Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trialBMC Cancer · 2021
  36. Comparison of neutralizing antibody responses against SARS‐CoV ‐2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?American Journal of Hematology · 2021
  37. Germline mutations in a clinic-based series of pregnancy associated breast cancer patientsBMC Cancer · 2021
  38. Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma PatientsCancers · 2021
  39. Blood transcriptomes of anti-SARS-CoV2 antibody positive healthy individuals with prior asymptomatic versus clinical infection2021
  40. Trastuzumab administration during pregnancy: an updateBMC Cancer · 2021
  41. The Emerging Role of Immunotherapy in Intrahepatic CholangiocarcinomaVaccines · 2021
  42. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOPThe Oncologist · 2021
  43. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine doseBlood · 2021
  44. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaJournal of Hematology & Oncology · 2021
  45. Age‐dependent and gender‐dependent antibody responses against SARS‐CoV ‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccineAmerican Journal of Hematology · 2021
  46. Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trialBritish Journal of Haematology · 2021
  47. European Myeloma Network perspective on CAR T-Cell therapies for multiple myelomaHaematologica · 2021
  48. Exercise-Induced Changes in Tumor Growth via Tumor ImmunitySports · 2021
  49. Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assaysScientific Reports · 2021
  50. Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myelomaAmerican Journal of Hematology · 2021